

Office	APPLICANT: Gerald W. DeMeyer		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE:	GROUP: 1731 ENTRANCE 2002 1644	
February 22, 2002			

### U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
PWK		5,443,505	08/22/1995	Wong et al.	623	4	8-22-95
PWK		5,869,079	02/09/1999	Wong et al.	424	426	2-9-99

### FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

PWK	Callanan et al., "Characteristics of Rejection of Orthotopic Corneal Allografts in the Rat," <u>Transplantation</u> 45:437-443 (1988)
	Clayson, "Corneal Lymphatics and Grafts," <u>The Lancet</u> 10:1291-1292 (1966)
	Cohen et al., "A platelet-activating factor antagonist reduces corneal allograft inflammation and neovascularization," <u>Curr. Eye Res.</u> 13:139-144 (1994)
	Collin, "Lymphatic drainage of <sup>131</sup> I-albumin from the vascularized cornea," <u>Invest. Ophthalmol.</u> 9:146-155 (1970)
	Collin, "Corneal lymphatics in alloxan vascularized rabbit eyes," <u>Invest. Ophthalmol.</u> 5:1-13 (1966)
↓	Cursiefen et al., "Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor α, and transforming growth factor β <sub>1</sub> in human corneas with neovascularization," <u>Cornea</u> 19:526-533 (2000)

EXAMINER <i>PL J. X</i>	DATE CONSIDERED <i>4/8/04</i>
----------------------------	----------------------------------

Initial if citation considered. Whether or not citation is in conformance with

and Trademark Office		APPLICANT: Gerald W. De Vries
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: February 22, 2002
		GROUP 3731 1644

<i>PNT</i>	Engh et al., "Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and H89," <i>J. Biol. Chem.</i> 271:26157-26164 (1996)
	Fine and Stein, "The role of corneal vascularization in human corneal graft reactions," In: <i>Corneal Graft Failure</i> (Ciba Foundation Symposium) pp. 193-204 Scientific Publishers: Amsterdam, Holland (1973)
	Foulks, "Clinical aspects of corneal allograft rejection," In: <i>Cornea: Surgery of the Cornea and Conjunctiva</i> (Krachmer et al., eds.) 138:1687-1696 (1997)
	Fournier et al., "Mutation at tyrosine residue 1337 abrogates ligand-dependent transforming capacity of the FLT4 receptor," <i>Oncogene</i> 11:921-931 (1995)
	Fournier et al., "Role of tyrosine residues and protein interaction domains of SHC adaptor in VEGF receptor 3 signaling," <i>Oncogene</i> 18:507-514 (1999)
	Fournier et al., "Interaction with the phosphotyrosine binding domain/phosphotyrosine interacting domain of SHC is required for the transforming activity of the FLT4/VEGFR3 receptor tyrosine kinase," <i>J. Biol. Chem.</i> 271:12956-12963 (1996)
	Galland, "The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor," <i>Oncogene</i> 8:1233-1240 (1993)
	Hagedorn and Bikfalvi, "Target molecules for anti-angiogenic therapy: from basic research to clinical trials," <i>Crit. Rev. Oncol. Hematol.</i> 34:89-110 (2000)
	Hennequin et al., "Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors," <i>J. Med. Chem.</i> 42:5369-5389 (1999)
	Joukov et al., "Vascular endothelial growth factors VEGF-B and VEGF-C," <i>J. Cell. Physiol.</i> 173:211-215 (1997)
✓	Junghans and Collin, "Limbal lymphangiogenesis after corneal injury: An autoradiographic study," <i>Curr. Eye Res.</i> 8:91-100 (1989)

EXAMINER <i>P. N. J.</i>	DATE CONSIDERED 4/8/04
-----------------------------	---------------------------

Commerce Patent  
and Trademark  
Office

APPLICANT: Gerald W. De Vries

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

FILING DATE:  
February 22, 2002

GROUP: 3731

MAY 1  
TECHNOLOGY  
SEARCHED  
INDEXED  
MAILED  
152002  
1604

P&K	Karkkainen and Petrova, "Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis," <u>Oncogene</u> 19:5598-5605 (2000)
	Kirkin et al., "Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2," <u>Eur. J. Biochem.</u> 268:5530-5540 (2001)
	Kirsch et al., "Anti-angiogenic treatment strategies for malignant brain tumors," <u>J. Neuro-oncol.</u> 50:149-163 (2000)
	Klagsbrun and D'Amore, "Vascular endothelial growth factor and its receptors," <u>Cytokine &amp; Growth Factor Rev.</u> 7:259-270 (1996)
	Korpelainen and Alitalo, "Signaling angiogenesis and lymphangiogenesis," <u>Curr. Opin. Cell Biol.</u> 10:159-164 (1998)
	Kubo et al., "Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis," <u>Blood</u> 96:546-553 (2000)
	Li and Eriksson, "Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D," <u>Inter. J. Biochem. Cell Biol.</u> 33:421-426 (2001)
	Liu et al., "Cytokine signaling through the novel tyrosine kinase RAFTK in Kaposi's sarcoma cells," <u>J. Clin. Invest.</u> 99:1798-1804 (1997)
	Maeno et al., "Three decades of corneal transplantation: Indications and patient characteristics," <u>Cornea</u> 19:7-11 (2000)
	Makinen et al., "Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3," <u>Nature Medicine</u> 7:199-205 (2001)
	McCallum et al., "Analysis of corneal and conjunctival microenvironments using monoclonal antibodies," <u>Invest. Ophthalmol. Vis. Sci.</u> 34:1793-1803 (1993)
	Millauer et al., "Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant," <u>Nature</u> 367:576-579 (1994)
✓	Mimura et al., "Expression of Vascular Endothelial Growth Factor C and Vascular Endothelial Growth Factor Receptor 3 in Corneal Lymphangiogenesis," <u>Exp. Eye Res.</u> 72:71-78 (2001)

EXAMINER

DATE CONSIDERED

4/8/04

whether or not citation is in conformance with

Commerce Patent  
and Trademark  
Office

APPLICANT: Gerald W. De Vries

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

FILING DATE:  
February 22, 2002

GROUP: 3731  
1644

PAK	Mohammadi et al., "Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain," <u>EMBO J.</u> 17:5896-5904 (1998)
	Naacke et al., "Outcome of corneal transplantation rejection," <u>Cornea</u> 20:350-353 (2001)
	Niederkorn, "The immunology of corneal transplantation," <u>Dev. Ophthalmol.</u> 30:129-140 (1999)
	Olofsson et al., "Current biology of VEGF-B and VEGF-C," <u>Curr. Opin. Biotech.</u> 10:528-535 (1999)
	Paavonen et al., "Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing," <u>Amer. J. Pathology</u> 156:1499-1504 (2000)
	Pajusola et al., "Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts," <u>Oncogene</u> 8:2931-2937 (1993)
	Pajusola et al., "FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines," <u>Cancer Research</u> 52:5738-5743 (1992)
	Pajusola et al., "Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors," <u>Oncogene</u> 9:3545-3555 (1994)
	Petrova et al., "Signaling via vascular endothelial growth factor receptors," <u>Exper. Cell Res.</u> 253:117-130 (1999)
	Stacker and Achen, "The vascular endothelial growth factor family: signalling for vascular development," <u>Growth Factors</u> 17:1-11 (1999)
	Taipale et al., "Vascular endothelial growth factor receptor-3," <u>Curr. Top. Microbiol. Immunol.</u> 237:85-96 (1999)
	Tong et al., "A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket," <u>Nature Struct. Biol.</u> 4:311-316 (1997)
✓	Treseler, "The expression of HLA antigens by cells in the human cornea," <u>Am. J. Ophthalmol.</u> 98:763-772 (1984)

EXAMINER

DATE CONSIDERED


4/8/04

Indicate if citation considered, whether or not citation is in conformance with  
37 CFR 1.57. If citation is not considered, include a brief statement of reason.

and Trademark Office	APPLICANT: Gerald W. De Vries	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: February 22, 2002	GROUP: 3501 1644

LOGIC 15 2002  
SEARCHED  
INDEXED  
FILED

PNK		Veikkola et al., "Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice," <u>EMBO J.</u> 20:1223-1231 (2001)
		Waldock and Cook, "Corneal transplantation: How successful are we?," <u>Br. J. Ophthalmol.</u> 84:813-815 (2000)
		Wang et al., "Signal transduction in human hematopoietic cells by vascular endothelial growth factor related protein, a novel ligand for the FLT4 receptor," <u>Blood</u> 90:3507-3515 (1997)
		Wedge et al., "ZD4190: An Orally Active Inhibitor of Vascular Endothelial Growth Factor Signaling with Broad-Spectrum Antitumor Efficacy," <u>Cancer Research</u> 60:970-975 (2000)
		Wilson et al., "The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase," <u>Chem. &amp; Biol.</u> 4:423-431 (1997)
↓		Zachary and Gliki, "Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family," <u>Cardiovascular Res.</u> 49:568-581 (2001)

EXAMINER 	DATE CONSIDERED 4/8/04
---	---------------------------

-----  
Indicates citation considered whether or not citation is in conformance with